---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-177024"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:12:48.390586+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reaches preliminary settlement in shareholder derivative lawsuit

## Summary
- Court preliminarily approved derivative settlement on July 29, 2025, with final hearing set for Nov 4, 2025.
- Settlement requires ImmunityBio to adopt corporate governance reforms including a new independent director and enhanced compliance.
- Attorneys' fees not to exceed $1.4 million will be paid by insurance; no monetary payment to shareholders.
- Governance reforms include quarterly board updates on FDA/cGMP compliance and annual legal department reviews.
- Settlement resolves derivative actions related to alleged oversight failures and misleading statements about Anktiva BLA.

## SEC filing metadata
- accession: 0001193125-25-177024
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312525177024/0001193125-25-177024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312525177024/d29656d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-177024
- JSON: https://secwatch.observer/filing/0001193125-25-177024.json
- Plain text: https://secwatch.observer/filing/0001193125-25-177024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.